TNF and amyotrophic lateral sclerosis: Preclinical studies on TNF-α inhibition using thalidomide and IMiDs in models of diseases such as ALS, PD, AD, and TBI have shown promise, indicating the potential for the advancement of select members of this drug class from the bench to clinical trials and eventually, to the bedside of patients of neurological disease in need of treatment.